Study of Delirium in Older Adults Treated With Ceftazidime, Cefepime, or Ceftriaxone for Infections

What this Trial Is About

Researchers are evaluating whether the use of the antibiotics ceftazidime, cefepime, and ceftriaxone affects the development of delirium in elderly patients aged 65 and older who are being treated for infections. This observational study aims to understand if these antibiotics increase delirium risk, how dose adjustments based on kidney and liver function impact this risk, and the severity and recovery time of delirium in this population. The study involves three groups of hospitalized older adults receiving one of the three antibiotics ceftazidime, cefepime, or ceftriaxone. Each group will include at least 40 patients treated for infections. Researchers will observe the patients antibiotic dosing, including any renal and hepatic adjustments, throughout their infection management. Participants will be assessed for delirium using the Confusion Assessment Method CAM at days 2, 4, and 6 after starting antibiotic treatment. Their overall health status will be tracked using scores like QSOFA and NEWS. If delirium occurs, its severity will be measured using the Delirium Rating Scale DRS-R98. The study will also monitor length of hospital stay, mortality rate, and time to delirium onset, with follow-up assessments up to 90 days after hospital admission.

Comparative Analysis of Delirium in Older Adults Treated With Ceftazidime, Cefepime, or Ceftriaxone